GlassScriptPhysician profile
Shara S Bledsoe
NPI 1063776607
$1,731.94
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $534 · 2023: $871 · 2024: $88.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $369.00 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $288.85 | 2022-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $238.99 | 2021-2023 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $169.90 | 2022-2023 | Xarelto |
| Abbott Laboratories | $91.26 | 2023-2024 | Freestyle Libre 3 |
| Pfizer INC. | $89.81 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.09 | 2022-2023 | Jardiance |
| Abbvie INC. | $50.75 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $40.78 | 2023 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $38.52 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.00 | 2022 | |
| Astellas Pharma US INC | $36.30 | 2023-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $31.96 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.24 | 2022 | |
| Glaxosmithkline, LLC. | $27.64 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.06 | 2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $24.78 | 2022 | |
| Genentech USA, INC. | $18.74 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.17 | 2023 | Quviviq |
| Exact Sciences Corporation | $17.10 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shara Bledsoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.